Management of Pregnancy-Induced Hypertension

Current Guideline Recommendations

The American College of Cardiology recommends labetalol and extended-release nifedipine as first-line agents for hypertension in pregnancy, with methyldopa as an alternative option 1, 2
The American Heart Association aligns with this recommendation, prioritizing labetalol and nifedipine over methyldopa for their superior side effect profiles and efficacy in preventing severe hypertension 1

Labetalol demonstrates superior prevention of disease progression, with 0% of patients developing significant proteinuria compared to 18.5% on methyldopa 1

The American College of Obstetricians and Gynecologists recommends switching from methyldopa to alternative agents postpartum due to the increased risk of postnatal depression associated with methyldopa 1
Labetalol has a superior tolerability profile, with fewer side effects and better maternal acceptance, and its main contraindication is reactive airway disease (asthma) 1

Labetalol may improve obstetric outcomes, with lower rates of labor induction and cesarean section for uncontrolled pregnancy-induced hypertension, and higher Bishop scores at induction suggesting a potential cervical ripening effect 1
Both labetalol and methyldopa have acceptable fetal safety profiles, with labetalol having minimal risks including potential fetal growth restriction, fetal bradycardia, and hypoglycemia, but no reports of teratogenicity 1

Labetalol requires more frequent dosing during pregnancy due to accelerated drug metabolism, and may need to be given as 200 mg orally initially, with escalation up to 2400 mg/day in divided doses 1
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) stated that methyldopa was preferred if delivery is likely more than 48 hours off due to its safety record 3

Peripheral edema, dry mouth, and lightheadedness can occur and may affect medication adherence in pregnant women taking methyldopa 4
Mood disturbances can occur during treatment, with methyldopa specifically being contraindicated in the postpartum period due to increased risk of postnatal depression, as recommended by the European Heart Association 5, 6

Beta-blockers and calcium channel blockers are more effective than methyldopa for the prevention of severe hypertension in pregnancy, according to the American Heart Association 4

The standard dose of methyldopa is 750 mg to 4 g per day in three or four divided doses, as suggested by the European Heart Association 7

Methyldopa should be avoided in the postpartum period due to increased risk of postnatal depression, as recommended by the European Heart Association 5, 6

Consider methyldopa as a potential first-line agent for hypertension in pregnancy, particularly when other agents are contraindicated or unavailable, as suggested by the European Heart Association and the American Heart Association 4, 7